Key Takeaways
- Morgan Cheatham is appointed head of health care and life sciences at Breyer Capital.
- At 29, Cheatham brings experience from Bessemer Venture Partners and holds a medical degree from Brown University.
- He is a prominent advocate for health AI, collaborating with major organizations in the field.
New Leadership in Health Investment
Morgan Cheatham has been appointed as the head of health care and life sciences at Breyer Capital, a firm led by Jim Breyer, an influential investor known for early stakes in successful companies such as Facebook and Etsy. With a focus on identifying transformative ideas in health care and life sciences, Cheatham is set to leverage his expertise and invest in promising ventures.
At just 29, Cheatham has already made significant contributions to the health tech space during his tenure at Bessemer Venture Partners, where he was instrumental in investments in notable digital health firms like Hinge Health, a virtual physical therapy provider that recently went public, and Abridge, a rapidly growing ambient scribing company.
Cheatham’s academic background further strengthens his credentials; he completed his medical degree at Brown University in May and subsequently began a residency in pediatrics and genetics at Boston Children’s Hospital and Harvard. His unique combination of clinical training and investment insight positions him well to navigate the evolving landscape of health technology.
In addition to his investment role, Cheatham is an advocate for artificial intelligence in the health sector. He collaborates with respected organizations such as the New England Journal of Medicine AI and the Coalition for Health AI, highlighting his commitment to advancing the integration of AI into healthcare practices. His vision focuses on unlocking the potential of innovative technologies to enhance patient care and streamline health services.
The content above is a summary. For more details, see the source article.
